2,323 results on '"Canonica, Giorgio"'
Search Results
2. Twenty-five years: The fexofenadine clinical experience
3. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma
4. Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
5. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma
6. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
7. Efficacy of 300 IR 5-grass sublingual immunotherapy tablet for allergic rhino-conjunctivitis
8. Local Allergic Rhinitis
9. Asthma patients' and physicians’ perspectives on the burden and management of asthma: Post-hoc analysis of APPaRENT 1 and 2 to assess predictors of treatment adherence
10. IR (index of reactivity)-house dust mite sublingual immunotherapy liquid formulation for allergic rhinoconjunctivitis: Systematic review and meta-analysis of randomized and nonrandomized studies
11. Respiratory allergic diseases and allergen immunotherapy: A French patient survey before and during the COVID-19 pandemic
12. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
13. A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma
14. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
15. Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis
16. Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial
17. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
18. Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab
19. Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus
20. Advancing precision medicine in asthma: Evolution of treatment outcomes
21. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
22. Update meta-analysis on the efficacy and safety issues of fexofenadine
23. A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma
24. The Prescribing Practice for COPD: Relationship to Circadian Rhythm, Disease Severity, and Clinical Phenotype in the STORICO Observational Study
25. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy
26. COPD and biologic treatment: state of the art
27. Questionnaire Validation: A User Guide for Allergy Research
28. Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group
29. Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps
30. Is asthma control more than just an absence of symptoms? An expert consensus statement
31. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma
32. Patients' and physicians’ perspectives on the burden and management of asthma: Results from the APPaRENT 2 study
33. WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates inCOVID-19
34. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life
35. Correction to: Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride
36. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study
37. Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride
38. Current treatment strategies for seasonal allergic rhinitis: where are we heading?
39. Rhinitis and Asthma Patient Perspective (RAPP): Clinical Utility and Predictive Value
40. Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
41. SANI Clinical Remission definition: a useful tool in Severe Asthma management.
42. WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates inCOVID-19
43. WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways
44. Exploring the Potential Role of Metabolomics in COPD: A Concise Review
45. Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study
46. Meta‐analysis in allergy—Statistical recommendations
47. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study
48. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
49. Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study
50. Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.